Current and Future Treatment Options - EU Perspective

  HCV in HIV EU Perspective_v1

2015 HCV in HIV

 

 

   

About the Program:

Program Overview:

As many as 7 million people worldwide are infected with both HIV and HCV. Because of the potential consequences of HCV infection, clinicians who care for HIV/HCV co-infected patients face many complex treatment issues, including when to start treatment, which treatments to use, how long to treat patients, and which treatments can be safely combined in this population. In addition, they must remain abreast of rapidly changing information on the treatment of HIV/HCV co-infected patients. This program, “Managing HCV in HIV-positive Patients: What Clinicians Need to Know,” is a series of six internet symposia, each covering a specific topic in the treatment of HIV/HCV co-infected patients. Each one hour symposium will feature an interview of an expert in the field of HCV treatment, who will review and discuss the most essential information and data HIV clinicians need to know.

The fifth internet symposium is being brought to you from Barcelona, Spain and will cover, “Current and Future Treatment Options - EU Perspective.” This one-hour program will feature an interview of Sanjay Bhagani, BSc FRCP, from Royal Free Hospital in London, England, and one of the leading experts on HIV management and treatment, by Jürgen Rockstroh, MD from University Hospital in Bonn, Germany.

Back to Top

Faculty:

Sanjay Bhagani, BSc FRCP
Consultant Physician
Infectious Diseases/HIV Medicine and General Medicine
Royal Free Hospital
London, England

Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Back to Top 

 

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Appropriately screen patients for HCV to identify HIV/HCV co-infected patients in their practice
  • Develop effective strategies for treating HCV in HIV-positive patients
  • Apply the most recent information to the treatment of HIV/HCV co-infected patients to avoid drug-drug interactions, minimize adverse effects, and achieve successful outcomes
  • Discuss research on HCV drugs in development to apply this information to ongoing treatment decisions

Release Date:  November 18, 2015

Expiration Date:  November 18, 2016

Estimated time to complete this program:  1 hour 

Media: Internet

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV and HCV infection.

Back to Top

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation:

The Postgraduate Institute for Medicine designates this this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top 

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

 

Juergen Rockstroh, MD

 

  • Consulting Fees: Abbvie, Bionor, BMS, Gilead, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Janssen, Merck, ViiV
  • Contracted Research: Gilead

Sanjay Bhagani, MD

  • Consulting Fees: Abbive, BMS, ViiV, Gilead, Merck
  • Contracted Research: Abbvie

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

 

Back to Top

Instructions for Participation and Credit:

 

There are no fees for participating and receiving CME credit for this activity. During the period, November 18, 2015 through November 18, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10696.  Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Back to Top

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Back to Top

 

 

PIM_small

VE logo 300px 

  This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs

 


Prepare to print

Share this page:

Get link code to this page     


Back to Top